



# COMMUNITY CONNECTION


Quarterly Newsletter

November 2022

---

**Study Accruals**


## ACTIVE STUDIES



\* Data through 11/03/2022

## Study Highlight

**WF-1806 Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study**



Myopenia & Mechanisms  
of Chemotherapy Toxicity


**PI: Grant R. Williams, MD**

University of Alabama at Birmingham

**Consortium PI: Glenn Lesser, MD**

Wake Forest NCORP Research Base

**Study Design:** This is a prospective cohort study that examines the impact of myopenia on toxicity and overall survival (OS) in older adults with newly diagnosed metastatic colorectal cancer (CRC) or newly recognized metastatic recurrence for CRC greater than 1 year from completion of treatment of non-metastatic CRC planning to receive systemic chemotherapy and/or immunotherapy. The study also explores the moderating influence of genetic variation in the association between myopenia and toxicity.



\*CT imaging is performed as part of routine care at baseline and every ~12 weeks during chemotherapy and/or immunotherapy to assess disease response.

<sup>†</sup>Clinical assessments include muscle strength, physical performance, questionnaire assessments, and PRO-CTCAE toxicity assessments.

<sup>¥</sup> Patients will be followed up to 1 year after diagnosis for survival only.

### Brief Eligibility Criteria:

- 1) Older adults (age ≥60y) with either newly diagnosed metastatic CRC or newly recognized metastatic recurrence of CRC greater than 1 year from completion of treatment of non-metastatic CRC.
- 2) Planning to undergo immunotherapy and/or 5-FU based chemotherapy as first line of treatment. 5-FU chemotherapy can be 5-FU alone or in combination with oxaliplatin and/or irinotecan; +/- immunotherapy. Capecitabine is also acceptable.
- 3) Estimated life expectancy ≥6 months. Patients enrolled on hospice are ineligible.

### **Top 3 Accruing CC Affiliates\***

Rank	Affiliates	Accruals
1	VA217 - Bon Secours Cancer Inst. at Reynolds Crossing (SCOR)	6
2	IL042 - John H Stroger Jr Hospital of Cook County (Stroger MU)	3
	GA106 - Lewis Cancer & Research Pavilion at Saint Joseph's/Candler (Georgia)	
3	SC058 - Tideland's Georgetown Memorial Hospital (MUSC MU)	2
	SC024 - Spartanburg Medical Center (Upstate)	
	NJ048 - Saint Peter's University Hospital (Atlantic)	
	MO042 - CoxHealth South Hospital (Ozarks)	
	MN001 - Regions Hospital (METROMIN)	
	MI017 - Trinity Health Saint Mary Mercy Livonia Hospital (MCRC)	
	AL002 - University of Alabama at Birmingham Cancer Center	

\* Data from 07/01/2022 - 09/30/2022

### **Top 5 Accruing CDDR Affiliates\***

Rank	Affiliates	Accruals
1	OK010 - Mercy Hospital Oklahoma City (Ozarks)	22
2	MO131 - St. Louis Cancer & Breast Inst.-Ballwin (Ozarks)	18
3	WI212 - ThedaCare Regional Cancer Center (WINCORP)	15
	MO021 - Mercy Hospital Saint Louis (Ozarks)	
4	SC024 - Spartanburg Medical Center (Upstate)	7
5	SC008 - Medical University of South Carolina (MUSC MU)	5

\* Data from 07/01/2022 - 09/30/2022

## Site Highlight: Heartland NCORP




Heartland  
Cancer Research



The Heartland Cancer Research NCORP (HCR) arose from the combined efforts of three NCI Community Clinical Oncology Programs (CCOPs): Central Illinois CCOP (CICCOP), Illinois Oncology Research Association CCOP (IORA CCOP) and Heartland CCOP, all of which had earned national recognition for excellence in community cancer research. The successful integration of these three components resulted in an NCORP based on a strong commitment to quality, an excellent staff, and a rich and successful heritage. One key to HCR's success has been the collegial and cooperative relationships among its core leadership and administrative staff since its inception. We are committed to community cancer research. By combining our resources and sharing best practices, HCR has become a more efficient and effective organization than our legacy CCOPs, allowing us ultimately to provide a more comprehensive menu of clinical trials to the communities we serve.

Led by Bryan A. Faller, MD, (pictured below) with support of senior leaders, HCR continues to attract enthusiastic, young investigators with recent training in current research methodologies, fresh perspectives on the science of oncology and on the fields of personalized medicine and immuno-oncology. In 2022 NCI awarded HCR with a platinum certificate for high overall accrual. Twenty investigators were awarded gold accrual certificates for 10-39 accruals for the previous NCORP year. An additional 19 investigators received silver awards for enrolling 5-9 clinical trial patients during the same grant year. Our physician investigators and staff continue their extensive involvement with the NCI and National Clinical Trials Network (NCTN). HCR has three investigators serving currently on NCI Steering and Task Force Committees: Dr. Bryan Faller, Dr. Pawl Dyk, and Dr. Paul Mehan.



**"Our mission is to offer innovative, appealing, and relevant clinical trials to the patients we serve throughout Illinois and Missouri. These include a wide variety of cancer control, prevention, cancer care delivery and treatment protocols. There is no better way to accomplish this mission than with the distinction and access afforded to us as an NCORP. It is a mission that is wholeheartedly embraced by all of the components of HCR."**

---

*Do you have site or staff that should be recognized? Please submit recommendations to [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu) with "Quarterly Newsletter Site/Staff Highlight" in the subject line.*

## Research Staff Spotlight: Amber Stone, RN

Amber came to us in December of 2021 with a nursing background involving women's health with no research background. She was incredibly impressive with how quickly she absorbed her training and began working with our breast disease group. She enveloped the role of breast research coordinator and became the primary coordinator for the WF -1804CD clinical trial in January of 2022. Amber took the role with 50 participants already enrolled and managed to keep their schedules up to date and then decided to challenge herself and enrolled an additional 19 participants.

She is constantly screening and communicating with our breast surgeons and medical oncologists and this helps to maintain the rapport and she is always striving to make the process as smooth as possible for the MD's to enroll participants.

Her focus on the operational processes required for this trial and others is exceptional and her ability to adapt and take on new projects is remarkable. She is a true valuable asset to our program and we feel that she deserves the "Highlight" opportunity. She is truly our "Highlight" and we would love to clone her or at least give her the ability to train and pass on her talents to others!

**\*\*Nominated by Dr. Alyssa Throckmorton and Team at TN143 - Baptist Memorial Hospital for Women**

---

*Do you have a site or study staff member that should be recognized? Please submit recommendations to [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu) with "Quarterly Newsletter Site/Staff Highlight" in the subject line.*



## **Top Accruing Investigators by Study**

(from 7/1/2022 - 09/30/2022)

### **WF-1801**

1. Michael Haughton, MD (1) – SC053, Prisma Health
2. Ahmet Tunceroglu, MD, PhD (1) –MI117, CRCWM

### **WF-1802**

1. Joseph Pennington, MD, PhD (6) - VA217, SCOR
2. Gopal Rao Desai, MD (2) - NJ048, Atlantic
2. John LeCraw Mikell, MD (2) - GA106, Georgia
2. Deimante Tamkus, MD (2) - IL042, Stroger MU

### **WF-1804CD**

1. Syed Zia Ul Huq, MD (10) - MO131, Ozarks
1. Heide A. Rodgers, MD (10) - MO021, Ozarks
2. Bethany Sleckman, MD (9) - MO021 & MO131, Ozarks

### **WF-1805CD**

1. Amarinthia Curtis, MD (5) - SC024, Upstate
1. Evan Graboyes, MD, MPH (5) - SC008, MUSC MU
2. LuAnn Harris, ACNP (4) - SC053, Prisma Health

### **WF-1806**

1. Grant Williams, MD (4) - AL002, UAB
1. Li Ding, MD (2), MI017, MCRC
2. 12 other investigators from 11 NCORPs with 1 accrual

### **WF-1901**

1. Sara Adams, MD (1) - SC058, MUSC MU
1. Catherine Burbage, MD (1) - SC058, MUSC MU
1. Daniel Anderson, MD (1) - MN001, MetroMin
1. Kelly Taunton, APRN, CNP (1) - MN028, MetroMin
1. Nemer El Mouallem, Jr, MD (1) - VA095, VCU MU
1. Patrick Fernandes, MD (1) - IL232, Carle
1. Anna Higham, MD (1) - IL168, Carle
1. Christopher Snead, MD (1) - LA014, GulfSouth MU

## **Top Accruing Investigators by Study**

(from 7/1/2022 - 09/30/2022)

### **WF-1801**

1. Michael Haughton, MD (1) - SC053, Prisma Health
2. Ahmet Tunceroglu, MD, PhD (1) - MI117, CRCWM

### **WF-1802**

1. Joseph Pennington, MD, PhD (6) - VA217, SCOR
2. Gopal Rao Desai, MD (2) - NJ048, Atlantic
2. John LeCraw Mikell, MD (2) - GA106, Georgia
2. Deimante Tamkus, MD (2) - IL042, Stroger MU

### **WF-1804CD**

1. Syed Zia Ul Huq, MD (10) - MO131, Ozarks
1. Heide A. Rodgers, MD (10) - MO021, Ozarks
2. Bethany Sleckman, MD (9) - MO021 & MO131, Ozarks

### **WF-1805CD**

1. Amarinthia Curtis, MD (5) - SC024, Upstate
1. Evan Graboyes, MD, MPH (5) - SC008, MUSC MU
2. LuAnn Harris, ACNP (4) - SC053, Prisma Health

### **WF-1806**

1. Grant Williams, MD (4) - AL002, UAB
1. Li Ding, MD (2), MI017, MCRC
2. 12 other investigators from 11 NCORPs with 1 accrual

### **WF-1901**

1. Sara Adams, MD (1) - SC058, MUSC MU
1. Catherine Burbage, MD (1) - SC058, MUSC MU
1. Daniel Anderson, MD (1) - MN001, MetroMin
1. Kelly Taunton, APRN, CNP (1) - MN028, MetroMin
1. Nemer El Mouallem, Jr, MD (1) - VA095, VCU MU
1. Patrick Fernandes, MD (1) - IL232, Carle
1. Anna Higham, MD (1) - IL168, Carle
1. Christopher Snead, MD (1) - LA014, GulfSouth MU

## **Top CC Accruing Investigator**

(from 07/01/2022 - 09/30/2022)



Joseph Pennington, MD, PhD -  
VA217, SCOR (6)

## **Top CCDR Accruing Investigators**

(from 07/01/2022 - 09/30/2022)



Syed Zia Ul Huq, MD-  
MO131, OZARKS (10)



Heide Rodgers, MD-  
MO021, OZARKS (10)

## Meet Wake Forest NCORP Research Base Staff: Tonya Henighan



Ms. Henighan joined our team in June, 2022 and completed her MPH from Liberty University. She has experience in research coordination and is part of the WF-1901, IMPACTS team. Ms. Henighan is also involved in our Spanish project involving PainTRAINER® which is a culturally appropriate pain coping skills training intervention for Spanish-Speaking Hispanic/Latinx Patients with Cancer Pain.

She is also faculty with Wake Forest Biomedical Graduate School as an instructor teaching Ethics. She enjoys gardening, arts & crafts, learning new things, and entertaining at home. Her newest hobby is baking sugar cookies with royal icing! Fun fact: She is a Golden Girls trivia champion! In her free time she tries to stay creative with family. Family time is very important to her, her four beautifully spirited daughters are her best teachers!

## **WF-1901 - Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)**



**If you haven't gotten involved....Now is the time!**

*Welcome to the Ozarks sites in Missouri, Oklahoma and Arkansas along with MetroMin sites in Maplewood Minnesota who just joined us!*

**We had a great response at the 2022 Annual Wake Forest NCORP Research Base Meeting.**

**A big THANK YOU to our NCI Leadership team for helping us get the word out!**

**<https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCT04462302&r=1>**



Pain occurs frequently in patients with cancer and has many causes.

**PAIN**  
can be from  
the tumor and/OR  
the treatment.

**PAIN**  
can be **acute** (short-term)  
or **chronic** (long-lasting).

**PAIN**  
can **continue**  
after successful  
cancer treatment  
ends.

Controlling  
**PAIN**  
is an **important**  
part of your cancer  
treatment plan.

NCI supports research to understand  
and treat all types of pain.


This is an important study which addresses PAIN in a novel way.

- Participants learn new methods for managing their own pain.
- Participants are not expected to stop taking their pain medications.
- Study is low burden for site coordinator and physician.
- Study is flexible with the option to do it all remotely.
- Participants who are randomized to the control arm of the study are invited to use the intervention on their own once they complete study.
- Participants receive a gift card at all 4 time-points.

## WF-1901-IMPACTS Study Schema & Summary

- **Screen, recruit, consent**
- **T1 (week 0)**
  - Baseline Assessment
  - Randomization to Groups:
    - painTRAINER
    - Enhanced Usual Care
- **T2 (week 10)**
  - Post-Intervention Assessments
- **T3 (week 22)**
  - 3-Month Follow-Up Assessments
- **T4 (week 34)**
  - 6-Month Follow-Up Assessments

*Enrollment to completion approx. 9 months*



**Contact us at [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu) for more information.**

## New Publications

Hughes RT, Ip ER, Urbanic JJ, Hu JJ, Weaver KE, Lively MO, Winkfield KM, Shaw EG, Baez Diaz L, Brown DR, Strasser J, Sears JD, & Lesser GJ. Smoking and Radiation-induced Skin Injury: Analysis of a Multiracial, Multiethnic Prospective Clinical Trial. *Clinical Breast Cancer*. 2022. <https://doi.org/10.1016/j.clbc.2022.09.003>

Ellis SD, Vaidya R, Unger JM, Stratton K, Gills J, Van Veldhuizen P, Mederos E, Dressler EV, Hudson MF, Kamen C, Neuman HB, Kazak AE, Carlos RC, & Weaver KE. Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey. *Contemporary Clinical Trials Communications*. 2022; 29:100981. <https://doi.org/10.1016/j.conctc.2022.100981>



Study	Abstract Title	Authors	Conference	Acceptance & Format	Conference Date	Conference location
OaSiS WF20817CD	Qualitative study of a facilitated strategy for implementing tobacco cessation support in lung screening facilities (oasis wf-20817cd)	Rebecca J. Stone, Sydney Evelyn Gibbs, Kathryn E. Weaver	Dissemination and Implementation	Poster Presentation in session: Clinical Care Settings: System-level Interventions 4:30 PM December 12, 2022	December 11-14, 2022	Washington, DC
OaSiS WF2817CD	Analytic Approaches to Incorporating Multi-Level Outcomes of Implementation Adoption and Fidelity in Cluster Randomized Trials (WF2817 CD)	Emily V. Dressler (presenter), Carol Kittel, Glenn J. Lesser, Kathryn Weaver, Caroline Chiles, Kristie Long Foley, Anna Snavelly	Dissemination and Implementation	Poster Presentation in session: Models, Measures, and Methods 8:00 AM December 13, 2022	December 11-14, 2022	Washington, DC
PREVENT WF98213	Examining the association between socioeconomic factors and left ventricular ejection fraction declines in breast cancer and lymphoma survivors receiving doxorubicin: WF-98213	Sutton, AL, O'Connell, NS, Lucas3, AR, Franco, RL, Reding, KW, Kim, Y, Cheng, R, Sheppard, VB, Weaver, KE, Lesser, GJ, Hundley, WG	American Heart Association	Moderated Digital Poster Session for in-person presentation	November 5-7 2022	Chicago, IL

UPBEAT WF97415	Longitudinal assessment of racial differences in exercise capacity after breast cancer treatment: WF-97415	Reding, KW, O'Connell, NS, Szewczyk, W, Cheng, RK, Nguyen, J, Ladd, A, Jordan, J, Lucas, A, Shepherd, V, Ge, Y, Salloum, F, Kim, Y, Lesnefsky, E, Franco, RL, Melendez, G, Sutton, A, D'Agostino Jr, R, Weaver, KE, Lesser, GJ, Hundley, WG	American Heart Association	Poster Session for in-person presentation	November 5-7 2022	Chicago, IL
UPBEAT WF97415	Hypertension Severity Impacts Declines in Left Ventricular Ejection Fraction Among Women Receiving Adjuvant Chemotherapy for Breast Cancer (UPBEAT WF-97415)	Garg, R, O'Connell, N, Lesser, GJ, Jordan, JH, Sutton, A, Bottinor, W, Ladd, A, D'Agostino Jr., R, Hundley, WG, the UPBEAT Study Team	American Heart Association	Poster Session for in-person presentation	November 5-7 2022	Chicago, IL
UPBEAT WF97415	How do chemotherapy and age affect physical performance in breast cancer patients over the first 3 months of treatment?	Bluethmann, S, Levine B, Mihalko S, Ansley K, Thomas A, Weaver KE, Lesser GJ, Hundley G, Klepin HD	Society of Geriatric Oncology conference	Poster Presented 19:00 – 21:00 on Friday 28 October	October 28-30 2022	International Conference Center Geneva

ACUPUNCTURE WF97115	The Effects of Acupuncture on Quality of Life (QOL) in Patients with Head and Neck Cancer Experiencing Chronic Radiation-Induced Xerostomia (RIX): Wake Forest NCI Community Oncology Research Program Research Base (WF NCORP RB) Randomized, Sham-controlled Trial WF-97115	Cohen L, Danhauer SC, Rosenthal DI, Chambers M, Garcia K, Cusimano A, Brown WM, Dressler EV, Ochoa J, Yang P, Chiang J, Gordon O, Crutcher R, Kim JK, Russin MP, Lukenbill J, Porosnicu M, Yost KJ, Weaver KE, Lesser GJ	Society for Integrative Oncology (SIO)	Oral presentation	October 20-22 2022	Scottsdale, AZ
BIOMARKERS 97609	Circulating bioenergetic signatures of radiation-induced skin toxicities in breast cancer patients (WF-97609)	Steven M. Bronson, Edward Ip, Emily Dressler, Kathryn E. Weaver, Glenn J. Lesser, David R. Soto-Pantoja	Radiation Research Society Annual Meeting	Poster Presentation	October 16-19 2022	Waikoloa Village, Hawaii

# Wake Forest NCI Community Oncology Research Program Research Base (WF NCORP RB)

## Clinical Trials Boot Camp

### Call for Applications

**Deadline: Friday, December 2<sup>nd</sup>, 2022, by 12pm EST**



**Overview:** This 2.5-day Wake Forest NCI Community Oncology Research Program Research Base (WF NCORP RB) clinical trials boot camp will be held February 6 – 8, 2023 at Graylyn Conference Center (<https://graylyn.com>) in Winston-Salem, NC. Each applicant will submit a basic trial concept (2-page max) for a Cancer Control or Cancer Care Delivery Research (CCDR) study suitable for community oncology to be fully developed during the boot camp. Protocols that are largely written before boot camp are likely not appropriate. Modeled after the AACR/ASCO Methods in Cancer Clinical Research workshop and WF Comprehensive Cancer Center boot camp for therapeutic oncology trials, the program will offer didactics related to clinical trial design, NCORP operations, feasibility and approval processes, recruitment of diverse populations, and biostatistical considerations. Lectures and discussions on how to develop protocols for inclusive and broad patient representation and participation will be led by leadership of the WF NCORP RB Health Equity Core. Boot camp lectures are mixed with intensive mentoring and feedback sessions from experienced NCORP investigators; active group participation through questions and feedback to others is expected of all participants. Additional information about



the Wake Forest NCORP Research Base is available at <https://wakencorp.phs.wakehealth.edu>.

Accepted participants will work with a mentoring team comprised of boot camp faculty with expertise in clinical care, cancer care delivery and implementation science, biostatistics and study design, and research and patient advocate perspectives. Additional mentors will be incorporated as needed to meet trainee needs, i.e., radiation or surgical oncology, hematology, adolescent, and young adult (AYA) research, etc. WF NCORP RB research staff will provide additional perspectives on feasibility and multi-site implementation.

The desired outcome of the 2.5 day in-person boot camp is a final study concept ready for development into a grant or full NCORP concept proposal to submit to the NCI Cancer Control or Cancer Care Delivery Research Steering Committee. Participating mentors have extensive experience developing NCI concepts and NIH (National Institutes of Health) grants for NCORP studies and will work with each participant to decide if additional pilot data may be needed to support the concept. If so, mentors will assist in developing a plan and budget for pilot activities.

Following boot camp, participants will meet monthly with mentors and peers to develop the desired final product (NCORP study concept for Steering Committee review or NIH grant). Participants will attend and present their concepts at the WF NCORP RB Annual Meeting October 2 – 3, 2023 in Asheville, NC as the culminating experience. At the annual meeting, boot camp participants will network with national NCORP leaders, receive feedback on their study concept from NCORP investigators, clinical research staff, and clinicians, and learn more about additional career development opportunities through this national research network.

### **Eligibility:**

1. Doctorally trained in any oncology specialty, including medical, surgical, radiation, gynecologic, and pediatric oncology, or faculty from other departments conducting cancer clinical research. Senior fellows may also apply (letter of support from current faculty mentor for fellow applicants strongly encouraged).
- Prioritization will be given to those new investigators (i.e., have not previously been a PI (Principal Investigator) or study chair for a WF NCORP RB study) who self-identify as members of groups underrepresented in the biomedical research enterprise (e.g., certain racial/ethnic groups, persons with disabilities, students from disadvantaged backgrounds, women, and other groups as described in the NIH Notice of Interest in Diversity) from academic institutions and/or NCORP Community and M/U Community sites.
2. The concept must focus on Cancer Control or Cancer Care Delivery Research; oncology treatment trials will not be responsive. Concepts proposing an interventional trial well-aligned with WF NCORP priorities that are feasible to

open within the NCORP community oncology network (<https://ncorp.cancer.gov/about/>) are strongly encouraged. When appropriate, concepts are encouraged to include biological mechanisms, correlative science, and a focus on underserved patient populations. Priorities include:

- Cancer Control
- Cardiovascular complications of cancer therapy
- Neurocognitive complications of cancer therapy
- Additional cancer and treatment-related symptoms (e.g., fatigue, pain) and related outcomes and supportive care interventions
- Cancer Care Delivery Research
- Delivery of comprehensive survivorship care
- Integrating informal or familial caregivers into cancer care
- Integration of evidence-based care in cancer care settings

**Funding:** WF NCORP RB will pay for participant expenses and travel to the boot camp in Winston-Salem, provide pilot funds to collect needed pilot feasibility data (where applicable), and to attend and present their concepts at the WF NCORP RB Annual Meeting in Asheville, NC.

**Additional Information:** Please contact WF NCORP RB at [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu) for more information.

**Deadline:** Please complete application and upload CV using the link below by **12pm EST on Friday, December 2<sup>nd</sup>, 2022.**

Click here to go to Boot Camp Application

<https://redcap.wakehealth.edu/redcapccc/surveys/?s=X387MTJFY9TMX347>

## Health Equity Core Updates

The Wake Forest NCORP Research Base Health Equity Core focuses on recruitment & retention of minority/underserved populations. This group meets quarterly to share best practices, influence study design, discuss community engagement strategies and share resources and tools. If you are interested in joining this group, please contact us at [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu)

We had a fabulous time at the Wake Forest NCORP Research Base Annual Meeting with plenty of discussion surrounding health equity and the barriers faced by patients and providers. Dr. Ray Osarogiagbon, Principal Investigator from Baptist MU NCORP was the keynote speaker. Dr. Osarogiagbon gave a very compelling presentation on equitable access to clinical trials and the barriers to participation.

We had a very interesting panel discussion made up of Alisha DeTroye, PA-C, Courtney Brown, and Leslie Byatt who shared their experiences from their sites on what they encounter when trying to recruit patients from underserved communities on clinical trials. They gave real life examples of barriers and the solutions their sites have tried and are doing to improve in this area. Dr. Karen Winkfield and Dr. Khalid Matin moderated the panel discussion (pictured below). A HEC luncheon was held at the Annual Meeting and Diamonique Suber, a patient advocate, relayed her cancer story to the group and the importance of having someone advocate for cancer patients as they begin their difficult journey.

Advocates for Research in Medicine (ARM) Fall Training was held Friday, October 28<sup>th</sup> and Saturday, October 29<sup>th</sup>. If your NCORP site is interested in having one or more of your staff trained in ARM, please reach out to Temana Aguilar at [Temana.Aguilar@wakehealth.edu](mailto:Temana.Aguilar@wakehealth.edu).





## **Wake Forest NCORP Research Base Annual Meeting Highlights**

The 9th Wake Forest NCORP Research Base Annual Meeting was held on October 10 & 11, 2022 in Myrtle Beach, SC. We would like to recognize some of our top accruing NCORP Sites and excellent research staff.

**Amber Stone, BSN, RN - WF-1804CD (AH-HA)**



**Bharathi Reddivari, Stroger - WF-1806 (M&M)**



**Abdelmohsen Alqalam, MD, Upstate - WF-1805CD (HN-STAR) & WF-1802 (PCW)**



**Barbara Roe, MUSC - WF97116 (REMEMBER)**



**Courtney Brown, Heartland - WF-1801 (RAMIPRIL) & WF-1901 (IMPACTS)**



## **WF NCORP RB Quarterly Calls**

The August 31st quarterly call Webex has been added to the Wake NCORP website. If you missed it -

Use this link to access the recording: <https://vimeo.com/746860089>

**Our next quarterly call is scheduled for January 11, 2023 at 3pm EDT.**

[Click here to add the January 11, 2023 Quarterly Call to your calendar](#)

**Recipe: Pumpkin Soup**



PHOTO: DOTDASH MEREDITH FOOD STUDIOS

### **Ingredients**

6 cups chicken stock  
4 cups pumpkin puree  
1 cup chopped onion  
1 clove garlic, minced  
1 ½ teaspoons salt  
½ teaspoon chopped fresh thyme  
5 whole black peppercorns  
½ cup heavy whipping cream  
1 teaspoon chopped fresh parsley

### **Directions**

Place chicken stock, pumpkin puree, onion, garlic, salt, thyme, and peppercorns in a large pot; bring to a boil. Reduce heat to low and simmer, uncovered, 30 minutes.

Transfer soup to a blender or food processor in batches; blend until smooth.

Return soup to the pan and bring to a boil; reduce heat to low and simmer, uncovered, for 30 minutes.

Stir in heavy cream. Ladle soup into bowls and garnish with fresh parsley.





minnesota cancer alliance  
working together to eliminate the burden of cancer

# CANCER CLINICAL TRIALS

<https://mncanceralliance.org>

I JOINED A CLINICAL TRIAL BECAUSE...

"Well, at first I didn't think I was eligible, but when I found a trial that was a good match; it was an easy decision to join."

- Thanh




FOR MORE INFORMATION, CALL 1-800-CANCER (1-800-422-6237) OR  
VISIT [HTTPS://WWW.CANCER.GOV/CONTACT](https://www.cancer.gov/contact)



minnesota cancer alliance  
working together to eliminate the burden of cancer

# CANCER CLINICAL TRIALS

<https://mncanceralliance.org>

I joined a clinical trial because...

"I am 84 and often think about the future of my grandchildren. If I can support medical research now, then I believe I am creating a healthier tomorrow for my family."

- Patricia




FOR MORE INFORMATION, CALL 1-800-CANCER (1-800-422-6237) OR  
VISIT [HTTPS://WWW.CANCER.GOV/CONTACT](https://www.cancer.gov/contact)

SketchQuotes by Nelle Rhicard at [www.reframeideas.com](http://www.reframeideas.com) [reframeideas.com]





*Copyright © 2022 Wake Forest NCORP Research Base, All rights reserved.*

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#).

